ID   Mel501A
AC   CVCL_0V14
SY   MEL501A; 501A; 501 A
DR   EFO; EFO_0006356
DR   ArrayExpress; E-MTAB-2706
DR   BioSample; SAMN03473285
DR   cancercelllines; CVCL_0V14
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001002554
DR   PharmacoDB; 501A_18_2019
DR   Wikidata; Q54905167
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=26589293;
RX   PubMed=29045385;
CC   HLA typing: A*02:01,03:01; B*07:02,14:02; C*07:02,08:02 (PubMed=26589293).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Cys275Trp (c.825T>G); ClinVar=VCV000485044; Zygosity=Unspecified (PubMed=29045385).
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: Metastatic; Not specified.
ST   Source(s): PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 10
ST   D13S317: 10,13
ST   D16S539: 14
ST   D18S51: 16
ST   D21S11: 29
ST   D3S1358: 14,16
ST   D5S818: 12
ST   D7S820: 10,12
ST   D8S1179: 12
ST   FGA: 24
ST   Penta D: 9
ST   Penta E: 7,13
ST   TH01: 9.3
ST   TPOX: 8,10
ST   vWA: 16,18
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_8054 ! 624-mel
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 08-07-15; Last updated: 05-10-23; Version: 14
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//
RX   PubMed=29045385; DOI=10.1038/nature24006;
RA   Kategaya L., Di Lello P., Rouge L., Pastor R., Clark K.R.,
RA   Drummond J., Kleinheinz T., Lin E., Upton J.-P., Prakash S.,
RA   Heideker J., McCleland M.L., Ritorto M.S., Alessi D.R., Trost M.,
RA   Bainbridge T.W., Kwok M.C.M., Ma T.P., Stiffler Z., Brasher B.,
RA   Tang Y.-Y., Jaishankar P., Hearn B.R., Renslo A.R., Arkin M.R.,
RA   Cohen F., Yu K.-B., Peale F.V., Gnad F., Chang M.T., Klijn C.,
RA   Blackwood E., Martin S.E., Forrest W.F., Ernst J.A., Ndubaku C.,
RA   Wang X.-J., Beresini M.H., Tsui V., Schwerdtfeger C., Blake R.A.,
RA   Murray J., Maurer T., Wertz I.E.;
RT   "USP7 small-molecule inhibitors interfere with ubiquitin binding.";
RL   Nature 550:534-538(2017).
//